Synopsis
The Union Health Ministry said in a statement on Monday that over 23,000 adverse events have been reported since the vaccination drive involving Covishield and Covaxin vaccines started in the country and of these 700 cases were reported to be serious.
ANI
Over 13.4 crore doses of Covishield vaccine have been administered as on 27 April in India.
India has reported 26 potential cases of bleeding and clotting after administration of Covishield vaccine, a government panel investigating adverse events following COVID-19 immunisation has found.
The Union Health Ministry said in a statement on Monday that over 23,000 adverse events have been reported since the vaccination drive involving Covishield and Covaxin vaccines started in the country and of these 700 cases were reported to be serious.
URL copied Image Source : PTI
A health worker administers a dose of Covishield vaccine to the citizens at a hospital in Dharavi in Mumbai.
Bleeding and clotting cases following COVID-19 vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country, a report submitted by the National AEFI (Adverse Event Following Immunization) Committee to the Ministry of Health & Family Welfare said.
Alerts have been raised in some countries on post-vaccination embolic and thrombotic events on 11 March, 2021 particularly with AstraZeneca-Oxford vaccine (Covishield in India). A decision was taken to conduct an urgent in-depth analysis of the adverse events (AE) in India in light of the global concerns.
Clotting after COVID vaccine minuscule in India
ANI
17 May 2021, 21:03 GMT+10
New Delhi [India], May 17 (ANI): The National Adverse Event Following Immunization (AEFI) Committee in its report submitted to the Union Health Ministry said that bleeding and clotting cases following COVID vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country.
According to a statement issued on Monday by the Ministry of Health and Family Welfare, alerts have been raised in some countries on post-vaccination embolic and thrombotic events on March 11 particularly with the AstraZeneca-Oxford vaccine (COVISHIELD in India). A decision was taken to conduct an urgent in-depth analysis of the adverse events (AE) in India in the light of the global concerns, the Health Ministry statement said.
Minuscule risk of blood clots with Covishield, no clots yet with Covaxin: Expert panel
The risk factor discovered by the committee in India is lower than the four cases per million found among those given Astrazeneca jabs in the UK.
Share Via Email
| A+A A- By Express News Service
NEW DELHI: A very minuscule but definitive risk of thromboembolic (blood clot) events 0.61 cases per million vaccinations has been seen among those administered the Covishield vaccine in India, the National Adverse Events Following Immunisation (AEFI) committee has said in a report to the Ministry of Health and Family Welfare.
Premier confident Bermuda will be added to UK green list royalgazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from royalgazette.com Daily Mail and Mail on Sunday newspapers.